Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26783070)
Watch
English
Optimizing therapy early in multiple sclerosis: An evidence-based view
scientific article
In more languages
edit
Statements
instance of
scholarly article
0 references
title
Optimizing therapy early in multiple sclerosis: An evidence-based view
(English)
0 references
main subject
multiple sclerosis
0 references
author
Tjalf Ziemssen
series ordinal
1
object named as
Tjalf Ziemssen
0 references
Bernd C Kieseier
series ordinal
6
object named as
Bernd C Kieseier
0 references
Heinz Wiendl
series ordinal
5
object named as
Heinz Wiendl
0 references
Nicola De Stefano
series ordinal
2
object named as
Nicola De Stefano
0 references
author name string
Maria Pia Sormani
series ordinal
3
0 references
Bart Van Wijmeersch
series ordinal
4
0 references
language of work or name
English
0 references
publication date
September 2015
0 references
published in
Multiple Sclerosis and Related Disorders
1 reference
stated in
PubMed
volume
4
0 references
issue
5
0 references
page(s)
460-9
0 references
cites work
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-JC virus antibodies: implications for PML risk stratification
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
JC virus antibody status underestimates infection rates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunopathogenesis of the multiple sclerosis lesion
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Switching therapies in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical relevance of brain volume measures in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Teriflunomide and its mechanism of action in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fingolimod: a review of its use in relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The molecular basis of neurodegeneration in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Mu
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The measurement and clinical relevance of brain atrophy in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association between pathological and MRI findings in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment optimization in MS: Canadian MS Working Group updated recommendations.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predicting responders to therapies for multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Determinants of interferon β efficacy in patients with multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Defining and scoring response to IFN-β in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorting out the risks in progressive multifocal leukoencephalopathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab treatment of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PML in a patient without severe lymphocytopenia receiving dimethyl fumarate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PML in a patient with lymphocytopenia treated with dimethyl fumarate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inflammatory cortical demyelination in early multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The role of magnetic resonance techniques in understanding and managing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evidence for a two-stage disability progression in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical outcome measures for research in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple sclerosis: current treatment algorithms.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Brain atrophy and lesion load predict long term disability in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalamic atrophy is associated with development of clinically definite multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Patterns of contrast enhancement in the brain and meninges
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Measures in the first year of therapy predict the response to interferon β in MS
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Scoring treatment response in patients with relapsing multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Refining response to treatment as defined by the Modified Rio Score.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evolving expectations around early management of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Best practice in the use of natalizumab in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gray matter damage predicts the accumulation of disability 13 years later in MS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Assessing treatment response to interferon-β: is there a role for MRI?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fingolimod after natalizumab and the risk of short-term relapse
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Defining the clinical course of multiple sclerosis: the 2013 revisions
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MRI predictors of cognitive outcome in early multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association of MRI metrics and cognitive impairment in radiologically isolated syndromes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Switching multiple sclerosis patients with breakthrough disease to second-line therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dimethyl fumarate for treating relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fingolimod for the treatment of relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/J.MSARD.2015.07.007
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
52787
OpenCitations bibliographic resource ID
52787
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
52787
PubMed publication ID
26346796
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
52787
ResearchGate publication ID
280716232
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit